Introduction
The rapidly activating delayed rectifier K + currents (I Kr ) critically contribute to cardiac repolarization (1) . The human ether-a-go-go-related gene, HERG, which is expressed in the heart of mammalian species including humans, encodes the pore-forming a subunit for I Kr (2) . Heterologously expressed HERG currents in mammalian cells including HEK293 and CHO cells are known to share pharmacological and biophysical properties with I Kr . Mutations in HERG are characterized by delayed ventricular repolarization, manifested on the electrocardiogram as a prolongation of QT interval (congenital long QT syndrome: LQTS) (3 -5) . A plethora of drugs including methanesulfonanilides (e.g., dofetilide, MK-499, and E-4031) are known to cause QT prolongation by blocking I Kr K + channels (acquired long QT syndrome), which is the underlying cause of life-threatening torsade de pointes, a form of polymorphic ventricular arrhythmia, in susceptible individuals (3, 6) . Syncope and sudden death due to torsade de pointes caused by noncardiovascular drugs such as terfenadine (antihistamine), astemizole (antihistamine), and cisapride (gastrokinetic) led to their withdrawal from the market (7, 8) . Consequently, cardiac safety relating to I Kr K + channels has become a major concern of regulatory agencies, as HERG channel inhibition has been identified as the firmest link to QT prolongation. In order to prevent costly attrition, it has become a high priority in drug discovery to screen out inhibitory activity on HERG channels in lead compounds as early as possible. Electrophysiological study using the patch clamp technique in HERG-transfected mammalian cells generates the most definitive data on HERG inhibition. However, the assay is slow and costly. Other functional assays using Rb flux or voltage-sensitive dyes have relatively low sensitivity, limiting their usefulness as efficient drug screens (9, 10) .
Given the fact that drug-induced blockade of I Kr is the primary cause of life-threatening arrhythmias, a [
3 H]astemizole binding assay in the HERG transfected embryonic kidney cell line HEK293 (11) was developed in order to provide a rapid and low-cost screen for HERG-binding activity. Astemizole is known to be a potent blocker of HERG channels (7, 12) . The assay was validated with 32 known HERG channel blockers with diverse structures. Furthermore, the radioligand binding data were compared with results from patch clamp studies. (11) .
Material and Methods

Reagents
Membrane preparation
Cell cultures of HERG transfected HEK293 cells were maintained in 90% Minimum Essential Medium, supplemented with 10% fetal bovine serum, 2 mM Lglutamine, and non-essential amino acids in a humidified incubator, 37°C, 5% CO 2 . Membranes were prepared from cell cultures following the method of Finlayson et al. (13) for small scale preparations or by modified methods for large scale production.
Small scale preparations employed cell monolayers, which were washed with Hank's Balanced Salt Solution (HBSS), then harvested by detachment with trypsin / EDTA, EDTA alone, or scraping into 0.32 M sucrose containing protease inhibitors (4 mg / mL aprotinin, 1 m g/ mL leupeptin, 100 mM 4-(2-amino-ethyl)benzenesulfonyl fluoride HCl [Pefabloc ® SC, AEBSF], and 1 m g / mL pepstatin A). Scraped cells remained in sucrose, while the others were centrifuged, resuspended in HBSS to wash them, centrifuged, and resuspended in 0.32 M sucrose and protease inhibitors. Cells were homogenized using a glass / Teflon tissue grinder. The suspension was centrifuged 10 min 650´g, 4°C and the supernatant was retained on ice during pellet resuspension in high purity H 2 O, 0°C. Following 10-min incubation, the pellet suspension was homogenized and centrifuged as above. The two supernatants were combined and centrifuged for 15 min at 48,000´g, 4°C. Pelleted membranes were resuspended and homogenized as before in membrane buffer (10 mM HEPES, pH 7.4, 5 mM KCl, 130 mM NaCl). Alternatively, large scale preparations employed cells grown in Cell Factories (Nunc, Rochester, NY, USA). Cells were rinsed with HBSS, detached with EDTA, washed, and resuspended in membrane buffer containing protease inhibitors. The cell suspension was disrupted using a Polytron tissue grinder (Kinematica, Lucerne, Switzerland) and centrifuged for 10 min at 700´g. The supernatant was centrifuged for 30 min at 48,000´g, 4°C. Pelleted membranes were resuspended and homogenized using a glass / Teflon tissue grinder in membrane buffer. Membrane protein was assessed by the BCA method (Pierce Biotechnology, Inc., Rockford, IL, USA), and aliquots were frozen in liquid nitrogen and stored at -80°C. Freshly thawed membranes were employed in all assays. H]astemizole. Non-specific binding (NSB) was defined by 10 m M astemizole. Incubation was conducted in 96-well polypropylene plates (Costar) at 25°C with equilibrium attainment experimentally verified at 60 min. Binding was terminated by rapid filtration onto GF / B glass fiber filtermats, presoaked in 0.3% polyethyleneimine, followed by rapid washing 6 times (2 mL) with ice-cold solution containing 25 mM 
Electrophysiological studies
HEK293 cells (11) were maintained in minimum essential medium with Earle's salts supplemented with nonessential amino acids, sodium pyruvate, penicillin, streptomycin, Geneticin ® and fetal bovine serum. The internal (composition: 130 mM KCl, 5 mM MgCl 2 , 10 mM HEPES, 5 mM EGTA, 5 mM ATP-Na 2 ) and external (137 mM NaCl, 4 mM KCl, 1 mM MgCl 2 , 1.8 mM CaCl 2 , 10 mM HEPES, 11 mM dextrose) recording solutions were adjusted to pH 7.2 using KOH and to pH 7.4 with NaOH, respectively. The vehicle was either de-ionized H 2 O or DMSO. Historical data from this lab indicate that over the course of approximately 10 min, 1% DMSO produced a 1.4 ± 1.5% (n = 11) reduction in HERG current amplitude. The lowest dilution used in the present study was 0.025% DMSO. Experiments were performed at 37 ± 1°C. Currents were measured using the whole-cell variant of the patch clamp method. Glass pipettes were pulled from borosilicate glass by a horizontal puller (Sutter Instruments, Novato, CA, USA) and then fire polished to produce tip openings of 1 to 2 m m for K + current recordings. Pipette tip resistance was approximately 1.0 to 2.0 MW when filled with K + internal solutions. Bath temperature was measured by a thermistor placed near the cell under study and was maintained by a thermoelectric device (model No. 806-7243-01, Cambion/ Midland Ross, Cambridge, MA, USA). An Axopatch 1-B amplifier (Axon Instruments, Foster City, CA, USA) was used for whole-cell voltage clamping. Creation of voltage clamp pulses and data acquisition were controlled by an IBM PC running pClamp software (Axon Instruments). After rupture of the cell membrane (entering whole-cell mode), current kinetics and amplitudes were allowed to stabilize as the cell was dialyzed with internal solution and paced at 0.1 Hz using protocol A (typically 5 -7 min). If the HERG current did not stabilize over this time period, the cell was discarded. Currents were considered stable if currents elicited by a series of voltage pulses given at 0.1 Hz were superimposed. Peak HERG current was measured as the maximum outward deflection of the tail current elicited upon return to -40 mV. Experiments were performed in the following order: establish wholecell configuration, dialyze cell and allow to reach steady-state condition, wash in the first concentration of the test drug, holding at -75 mV pulse at 0.1 Hz until steady state block is observed, wash in subsequent concentrations of drug (Fig. 6 ).
Data analyses
For binding studies, the final concentration of [ 3 H]astemzole was calculated using the following equation: Intraassay variation was calculated as the average of daily %CV, where %CV = (standard deviation / mean value)´100. Interassay variation was calculated employing the mean and standard deviation of individual experimental means. Percent CV for 7 separate experiments was determined by dividing standard deviation with mean value. The electrophysiological data are presented as percent reduction of current amplitude. This was measured as current reduction after a steadystate effect had been reached in the presence of drug relative to current amplitude before drug was introduced (control). Each cell served as its own control. Potency ranking is expressed in terms of the concentration that causes 50% reduction of current amplitude (IC 50 ) in nM.
Results
Optimization of assay conditions for [
3
H]astemizole binding using HERG transfected membranes
Astemizole binding to HERG increased with protein concentration with 91% specific binding observed at 100 m g/ mL and 95% at 400 m g/ mL (Fig. 1) . The concentration of [
3 H]astemizole employed equated to approximately 14,000 to 18,000 cpm per well. The final assay radioligand concentration consistently was found to be in the range of 1.4 to 1.8 nM. In subsequent assays, a protein concentration of 10 mg (100 m g / mL) per well was selected to avoid radioligand depletion. At this protein concentration, the obtained 8.5% bound radioligand allowed testing under acceptable zone A conditions (GraphPad Prism software, San Diego, CA, USA) and ensured a reliable window between total and non-specific binding. A comparison of specifically bound [ 3 H]astemizole to the HERG transfected HEK293 cell membrane preparation and wild-type HEK293 cell membrane preparation is shown in Fig. 1. [ 3 H]Astemizole binding above background was observed in the wild-type HEK293 cell membrane preparation at detectable levels. However, specifically bound signals were at least 8-fold higher in the transfected membrane preparations.
Time course of [ 3 H]astemizole binding in HERG transfected membranes
Binding equilibrium was attained by 60 min and binding levels remained constant for at least 180 min at 25°C (Fig. 2) . A 60-min standard incubation time was subsequently selected for all assays.
Concentration dependence of [
3 H]astemizole binding in HERG transfected membranes [ (Fig. 3) . Membranes prepared in small and large-scale formats were essen- 
Intraassay and interassay variations
Intraassay variation for the [ 3 H]astemizole binding assay, based on results from seven separate assays (n = 8 -32 each), was 11.4%, whereas interassay variation was 14.9% (2,557 ± 380 cpm, n = 7). The results speak for a robust [
3 H]astemizole binding assay for HERG.
Effect of DMSO on [ 3 H]astemizole binding in HERG transfected membranes
The concentration of DMSO in the assay buffer of up to 2% had little effect on [
3 H]astemizole binding (Fig. 4) . The final concentration of DMSO used in competition assays was 1%. Test compounds could be dissolved in 100% DMSO in mM concentrations which allowed top test concentrations of 10 m M or greater. Fig. 6 with ziprasidone. Data trended upward rising above lower plateaus defined by lower compound concentrations.
Such elevated values may have been due in part to poor solubility at high concentrations, although other compounds (e.g., tamoxifen) did not show this behavior despite evident poor solubility. Data corresponding to such high concentrations were excluded from curve fitting for K i estimations.
Comparison of binding data with electrophysiology data
The IC 50 values (n = 5 -7) for inhibition of HERG currents in HEK293 cells by 14 compounds were as follows: cisapride, 6.9 nM; E-4031, 18.1 nM; amiodarone, 25.9 nM; astemizole, 26 nM; fluoxetine, 197 nM; tamoxifen, 198 nM; imipramine, 616 nM; flecainide, 810 nM; ketoconazole, 1,920 nM; procainamide, 7,450 nM; disopyramide, 9,640 nM; and erythromycin, 62,600 nM. The effect of I Kr blockers on HERG currents is depicted in Fig. 7 , using astemizole as an example.
In comparison with [
3 H]astemizole binding data generated with the same compounds in HEK 293, it was demonstrated that the rank order of affinity (K i ) was highly correlative to that of inhibitory potency in the electrophysiology studies for HERG in HEK 293 (r SP = 0.91, P<0.005) (Fig. 8) . Furthermore, the 32 reference compounds including the 14 compounds from diverse structural classes demonstrated binding affinity values for HERG with similar rank order of inhibition of HERG currents as reported in the literature (6) . However, the potency for HERG inhibition in the binding assay is in general about one order of magnitude less than that in the electrophysiology assays (Fig. 8) . to key binding sites (Tyr652 and Phe656) for methanesulfoanilide compounds such as dofetilide, E4031, and MK499; the external entry to the channel pore has binding sites for toxins and blockers as well (4 
